Logo

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Share this
Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Shots:

  • The EC has granted marketing authorisation for Celltrion's regdanvimab in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progressing to severe COVID-19
  • The approval is based on the P-III trial to evaluate the efficacy & safety of regdanvimab in 1315+ patients with COVID-19 across 13 countries including the US, Spain & Romania. The results showed a 72% reduction in risk of COVID-19 related hospitalization or death in high-risk patients
  • The company is currently discussing with the US FDA regarding submission of an application for a EUA & has reported the development of a neutralizing Ab cocktail with CT-P59 against new emerging variants of SARS-CoV-2

/ article Ref: Celltrion | Image: HT

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions